A detailed history of Prelude Capital Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Prelude Capital Management, LLC holds 10,220 shares of BPMC stock, worth $936,356. This represents 0.06% of its overall portfolio holdings.

Number of Shares
10,220
Previous 10,220 -0.0%
Holding current value
$936,356
Previous $944,000 -0.0%
% of portfolio
0.06%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $859,502 - $1.23 Million
10,220 New
10,220 $944,000
Q1 2022

May 16, 2022

SELL
$54.1 - $110.08 $484,195 - $985,216
-8,950 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $94 - $115
-1 Reduced 0.01%
8,950 $959,000
Q3 2021

Nov 15, 2021

BUY
$80.98 - $109.47 $81,060 - $109,579
1,001 Added 12.59%
8,951 $920,000
Q2 2021

Aug 16, 2021

BUY
$82.78 - $101.0 $658,101 - $802,950
7,950 New
7,950 $699,000
Q4 2020

Feb 16, 2021

SELL
$92.08 - $124.48 $87,476 - $118,256
-950 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$66.45 - $92.7 $63,127 - $88,065
950 New
950 $88,000
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $360,825 - $616,650
-7,500 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$66.73 - $82.59 $500,475 - $619,425
7,500 New
7,500 $601,000
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $417,968 - $681,112
-9,172 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$58.91 - $78.32 $329,483 - $438,043
5,593 Added 156.27%
9,172 $716,000
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $218,175 - $362,123
3,579 New
3,579 $227,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.